서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 481 to 540 of 565

Issue DateTitle / Author(s) / CitationFileAltmetrics
2021-08
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
DOI
2021-08
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2,-3 and-7 trials in hormone receptor-positive, HER2-negative advanced breast cancer
DOI
2021-08
Genomic Profiling of Premenopausal HR+ and HER2-Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib
DOI
2021-08
Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts
DOI
2021-09
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer
DOI
2021-10
Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11)
DOI
2021-10
Lymph Node Ratio after Neoadjuvant Chemotherapy for Stage II/III Breast Cancer: Prognostic Value Measured with Gini's Mean Difference of Restricted Mean Survival Times

Keam, Bhumsuk; Gorobets, Olena; Vinh-Hung, Vincent; Im, Seock-Ah

Cancer Informatics, Vol.20, pp.1-9

DOI
2021-10
Talazoparib versus Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial

Lee, Kyung-Hun; Sohn, Joohyuk; Goodwin, Annabel; Usari, Tiziana; Lanzalone, Silvana; Im, Seock-Ah; Kim, Sung-Bae

Cancer Research and Treatment, Vol.53 No.4, pp.1084-1095

DOI
2021-10
Corrigendum to Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024](S0923753421015532)(10.1016/j.annonc.2021.05.353)
DOI
2021-10
Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer
DOI
2021-11
EFFECTS OF PEMBROLIZUMAB ON THE TUMOR MICROENVIRONMENT (TME) AFTER ONE PRESURGERY TREATMENT CYCLE IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER (TNBC): PHASE 1B KEYNOTE-173 STUDY
DOI
2021-12
Novel prognostic classification predicts overall survival of patients receiving salvage whole-brain radiotherapy for recurrent brain metastasis from breast cancer: A recursive partitioning analysis (KROG 16-12)
DOI
2021-12
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
DOI
2022
Do posttraumatic stress symptoms predict trajectories of sleep disturbance and fatigue in patients with breast cancer? A parallel-process latent growth model
DOI
2022-01
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer
DOI
2022-02
Morning Chronotype Decreases the Risk of Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer
DOI
2022-02
The impact of race and ethnicity in breast cancer-disparities and implications for precision oncology
DOI
2022-02
Trastuzumab Emtansine plus Pertuzumab Versus Taxane plus Trastuzumab plus Pertuzumab after Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study
DOI
2022-02
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
DOI
2022-03
HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis
DOI
2022-03
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
DOI
2022-03
Psychiatric symptoms mediate the effect of resilience on health-related quality of life in patients with breast cancer: Longitudinal examination
DOI
2022-03
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study
DOI
2022-03
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2(-) Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
DOI
2022-04
A Real-World Efficacy of Nab-Paclitaxel Monotherapy in Metastatic Breast Cancer
DOI
2022-04
Radiation Response Prediction Model Based on Integrated Clinical and Genomic Data Analysis
DOI
2022-04
Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
DOI
2022-05
VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer
DOI
2022-05
Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection
DOI
2022-06
Trastuzumab Deruxtecan for Breast Cancer REPLY

Cortés, Javier; Im, Seock-Ah; Cathcart, Jillian

New England Journal of Medicine, Vol.386 No.24, pp.2347-2347

DOI
2022-06
The longitudinal effects of chronotype on chemotherapy-induced nausea and vomiting in patients with breast cancer receiving neoadjuvant chemotherapy
DOI
2022-06
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2− Advanced Breast Cancer in the MONALEESA-3 Trial
DOI
2022-07
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
DOI
2022-07
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
DOI
2022-08
Do posttraumatic stress symptoms predict trajectories of sleep disturbance and fatigue in patients with breast cancer? A parallel-process latent growth model
DOI
2022-08
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2(- )ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
DOI
2022-09
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial
DOI
2022-10
Musculoskeletal Pain and the Prevalence of Rheumatoid Arthritis in Breast Cancer Patients During Cancer Treatment: A Retrospective Study

Kim, Ju Yeon; Kim, Min Jung; Lee, Eun Bong; Kim, Tae-Yong; Lee, Kyung-Hun; Im, Seock-Ah; Park, Jin Kyun

Journal of Breast Cancer, Vol.25 No.5, pp.404-414

DOI
2022-10
The Pattern of Care for Brain Metastasis from Breast Cancer Over the Past 10 Years in Korea: A Multicenter Retrospective Study (KROG 16-12)
DOI
2022-10
Role of Local Treatment for Oligometastasis: A Comparability-Based Meta-Analysis
DOI
2022-11
Prognostic role of tumor subtype and germline BRCA mutation in advanced breast cancer patients treated with palbociclib plus endocrine therapy
DOI
2022-11
The Effect of Temperament on the Association Between Pre-treatment Anxiety and Chemotherapy-Related Symptoms in Patients With Breast Cancer
DOI
2022-11
Prospective longitudinal analysis of antibody response after standard and booster doses of SARS-COV2 vaccination in patients with early breast cancer
DOI
2022-12
Evaluation of Seropositivity After Standard Doses of Vaccination Against SARS-CoV-2 in Patients With Early Breast Cancer Receiving Adjuvant Treatment
DOI
2022-12
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3
DOI
2022-12
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Geyer, C.E.; Garber, J.E.; Gelber, R.D.; Yothers, G.; Taboada, M.; Ross, L.; Rastogi, P.; Cui, K.; Arahmani, A.; Aktan, G.; Armstrong, A.C.; Arnedos, M.; Balmana, J.; Bergh, J.; Bliss, J.; Delaloge, S.; Domchek, S.M.; Eisen, A.; Elsafy, F.; Fein, L.E.; Fielding, A.; Ford, J.M.; Friedman, S.; Gelmon, K.A.; Gianni, L.; Gnant, M.; Hollingsworth, S.J.; Im, S.-A.; Jager, A.; Johannsson, O.Th.; Lakhani, S.R.; Janni, W.; Linderholm, B.; Liu, T.-W.; Loman, N.; Korde, L.; Loibl, S.; Lucas, P.C.; Marme, F.; Martínez de Dueñas, Eduardo; McConnell, R.; Phillips, K.-A.; Piccart, M.; Rossi, G.; Schmutzler, R.; Senkus, Elżbieta; Shao, Z.; Sharma, P.; Singer, C.F.; Spanic, T.; Stickeler, E.; Toi, M.; Traina, T.A.; Viale, G.; Zoppoli, G.; Park, Y.H.; Yerushalmi, R.; Yang, H.; Pang, D.; Jung, K.H.; Mailliez, A.; Fan, Z.; Tennevet, Isabelle; Zhang, J.; Nagy, T.; Sonke, G.S.; Sun, Q.; Parton, M.; Colleoni, M.A.; Schmidt, M.; Brufsky, A.M.; Razaq, Wajeeha; Kaufman, B.; Cameron, D.; Campbell, C.; Tutt, A.N.J.; the OlympiA Clinical Trial Steering Committee and Investigators; Im, Seock-Ah

Annals of Oncology, Vol.33 No.12, pp.1250-1268

DOI
2023-01
Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations
DOI
2023-01
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
DOI
2023-01
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial
DOI
2023-04
A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
DOI
2023-04
Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial
DOI
2023-05
Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1)
DOI
2023-05
OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician?s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
DOI
2023-05
Genetic and immune microenvironment characterization of HER2-positive gastric cancer: Their association with response to trastuzumab-based treatment
DOI
2023-05
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR+/HER2-early breast cancer
DOI
2023-05
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
DOI
2023-06
A Survey of Practice Patterns for Clinical Nodal Staging Prior to Neoadjuvant Chemotherapy in Breast Cancer
DOI
2023-06
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer
DOI
2023-07
Eflapegrastim versus Pegfilgrastim for Chemotherapy-Induced Neutropenia in Korean and Asian Patients with Early Breast Cancer: Results from the Two Phase III ADVANCE and RECOVER Studies
DOI
2023-07
IFI16/Ifi202 released from breast cancer induces secretion of inflammatory cytokines from macrophages and promotes tumor growth

Lim, Ga Young; Cho, Sun Wook; Ka, Na-Lee; Lee, Kyung-Hun; Im, Seock-Ah; Kim, Seung-Su; Hwang, Sewon; Lee, Mi-Ock

Journal of Cellular Physiology, Vol.238 No.7, pp.1507-1519

DOI
15 6 7 8 9 10